Enhanced payload localization in antibody-drug conjugates using a middle-down mass spectrometry approach with proton transfer charge reduction

Luca Fornelli,Linda Lieu,Cynthia Nagy,Jingjing Huang,Christopher Mullen,Graeme McAlister,Vlad Zabrouskov,Kristina Srzentić,Kenneth Durbin,Rafael Melani

DOI: https://doi.org/10.26434/chemrxiv-2024-qm5lh

2024-06-27

Abstract:Antibody-drug conjugates (ADCs) represent a novel class of immunoconjugates with growing therapeutic relevance since they combine the efficacy of cytotoxic drugs with the specificity of antibodies. However, by design, ADCs introduce structural features to the mAb scaffold that complicate their analysis. Payload attachment to cysteine or lysine residues can often result in product heterogeneity regarding both the number of attached drug molecules and their conjugation site, necessitating the use of state-of-the-art MS instrumentation to elucidate their complexity. In middle-down mass spectrometry (MD MS), the gas-phase sequencing of ~25 kDa ADC subunits with dif-ferent ion activation techniques generally produces rich fragmentation mass spectra; however, spectral congestion can cause some fragment ions to go undetected, includ-ing those that can pinpoint the exact location of payload conjugation sites. Proton transfer charge reduction (PTCR) can substantially simplify fragment ion spectra, thereby unveiling the presence of product ions whose signals were previously sup-pressed. Herein, we present an MD MS strategy relying on the use of PTCR to investi-gate a cysteine-based ADC mimic with a variable drug-to-antibody ratio, targeting the unambiguous localization of payload conjugation sites. Unlike traditional tandem MS experiments (MS2), which could not provide a full map of conjugation sites, a single PTCR-based experiment (MS3) proved to be sufficient to achieve this goal across all variably modified ADC subunits, including isomeric ones. Combining the results ob-tained from orthogonal ion activation techniques followed by PTCR further strength-ened the confidence in assignments.

Chemistry

What problem does this paper attempt to address?

The problem this paper attempts to address is the complexity of payload localization in antibody-drug conjugates (ADCs). Specifically, due to the structural characteristics of ADCs (such as different drug-to-antibody linkage sites and quantities), the product heterogeneity is high, making the analysis and characterization of these molecules very difficult. Traditional tandem mass spectrometry (MS2) methods cannot fully reveal the precise linkage sites of the payload, especially in ADCs with variable drug-to-antibody ratios (DAR). To overcome this challenge, the authors propose a method based on middle-down mass spectrometry (middle-down MS) combined with proton transfer charge reduction (PTCR) technology. This method can significantly simplify the fragment ion spectra, thereby revealing previously suppressed product ion signals, particularly those diagnostic fragment ions that can precisely locate the payload linkage sites. Through this method, the authors are able to achieve unambiguous localization of payload linkage sites for all differently modified ADC subunits, including isomers, in a single experiment.

Enhanced payload localization in antibody-drug conjugates using a middle-down mass spectrometry approach with proton transfer charge reduction

Digestion-Free Middle-down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from ADCs

Digestion-Free Absolute Quantification of Conjugated Payload from ADCs Using Middle-Down Fragmentation Mass Spectrometry

Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools

Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug Conjugates

A combination of multiple LC-MS approaches for the comprehensive characterization of cysteine-linked ADCs

Drug Deconjugation-assisted Peptide Mapping by LC-MS/MS to Identify Conjugation Sites and Quantify Site Occupancy for Antibody-drug Conjugates

Quantifying payloads of antibody‒drug conjugates using a postcolumn infused-internal standard strategy with LC‒MS

Conjugation site characterization of antibody-drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD)

Development of fine-tuned top-down mass spectrometry strategies in the chromatographic time scale (LC-TD-MS) for the complete characterization of an anti EGFR single domain antibody-drug conjugate (sdADC)

Towards a universal method for middle-down analysis of antibodies via proton transfer charge reduction – Orbitrap mass spectrometry

A simple and highly sensitive LC–MS workflow for characterization and quantification of ADC cleavable payloads

Intact quantitation of cysteine‐conjugated antibody‐drug conjugates using native mass spectrometry

Conjugation Site Analysis of Antibody-Drug-conjugates (adcs) by Signature Ion Fingerprinting and Normalized Area Quantitation Approach Using Nano-Liquid Chromatography Coupled to High Resolution Mass Spectrometry.

In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry

Detection of antibody-conjugate payload in cynomolgus monkey serum by a high throughput capture LC-MS/MS bioanalysis method

Enhanced Pharmacokinetic Bioanalysis of Antibody–drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS

Internal Fragments Enhance Middle-Down Mass Spectrometry Structural Characterization of Monoclonal Antibodies and Antibody-Drug Conjugates

A homogeneous high-DAR antibody-drug conjugate platform combining THIOMABTM antibodies and XTEN polypeptides

Detailed Structural Elucidation of an Antibody-Drug Conjugate, AZD8205, Biotransformation Species Using LC-MRM with CID and EAD Fragmentation

Imaged Capillary Isoelectric Focusing Coupled to High‐Resolution Mass Spectrometry (icIEF‐MS) for Cysteine‐Linked Antibody–Drug Conjugate (ADC) Heterogeneity Characterization Under Native Condition